サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1738685

組織マイクロアレイの世界市場規模：手技別、技術別、エンドユーザー別、地域範囲別、予測

Global Tissue Microarray Market Size By Procedure, By Technology, By End-User, By Geographic Scope And Forecast

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
組織マイクロアレイの世界市場規模：手技別、技術別、エンドユーザー別、地域範囲別、予測
出版日: 2025年05月02日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

組織マイクロアレイの市場規模と予測

組織マイクロアレイ市場規模は、2024年に111億7,000万米ドルと評価され、2026年から2032年にかけて10.04%のCAGRで成長し、2032年には212億9,000万米ドルに達すると予測されています。

  • 組織マイクロアレイ（TMA）は、分子病理学や研究で使用されるハイスループット技術で、1枚の顕微鏡スライド上で複数の組織サンプルを同時に解析します。TMAは、1回の実験で数百から数千の組織標本にわたる遺伝子発現、タンパク質局在、分子マーカーの効率的な検査を可能にします。
  • TMAは腫瘍学研究において、腫瘍の不均一性の研究、バイオマーカーの同定、分子プロファイルと臨床転帰との相関の研究に広く用いられています。TMAは、潜在的な治療標的や予後指標を探すための組織サンプルの大規模スクリーニングを容易にします。
  • 製薬会社はTMAを利用して、様々な組織タイプにおける薬剤の有効性と毒性を評価しています。TMAは、疾患に関与する特定のバイオマーカーや細胞経路に対する潜在的な薬剤候補の迅速なスクリーニングを可能にします。
  • 臨床の場では、TMAは特定の分子マーカーや遺伝子異常について組織サンプルを評価することにより、疾患の診断に役立ちます。TMAは、病理医が患者の予後や治療戦略について十分な情報を得た上で決断を下すためのサポートとなります。
  • 自動化の改善、サンプルスループットの向上、イメージングとデータ解析技術の強化など、TMA技術の継続的な進歩により、研究ワークフローはさらに合理化され、効率が向上します。

世界の組織マイクロアレイ市場力学

世界の組織マイクロアレイ市場を形成している主な市場力学は以下の通りです。

主な市場促進要因

  • 精密医療の進歩：個々の患者プロファイルに基づく標的治療の必要性により、個別化医療へのシフトが組織マイクロアレイ市場の重要な促進要因となっています。TMAにより、研究者は治療反応や患者の転帰をより正確に予測できるバイオマーカーを同定・検証できます。
  • がんの発生率の上昇：世界のがんの有病率の増加は、腫瘍組織の包括的な分子プロファイリングを容易にするTMAのような革新的なツールに対する需要を煽る。TMAは、がんの進行、転移、治療抵抗性に関連するバイオマーカーを同定することで、腫瘍学研究において重要な役割を果たしています。
  • 技術の進歩：自動化、デジタル画像化、ハイスループット解析機能など、TMA技術の絶え間ない進歩により、バイオマーカー探索および検証研究の効率と精度が向上しています。こうした技術革新は、迅速な納期とデータの質の向上をもたらし、研究者を惹きつけています。
  • バイオマーカー研究への注目の高まり：がんに限らず、様々な疾患においてバイオマーカー探索が重視されるようになってきています。TMAは神経変性疾患、心血管疾患、感染症に関連するバイオマーカーの探索に役立っており、その応用範囲は腫瘍学以外にも広がっています。
  • 医薬品開発と臨床試験：製薬企業は、薬剤開発や臨床試験において、薬剤反応や毒性プロファイルを予測できるバイオマーカーの同定にTMAを活用しています。TMAは患者コホートの選択を合理化し、治療開発プロセスの効率を向上させる。
  • 共同研究イニシアティブ：学術機関、研究機関、バイオテクノロジー企業間の協力関係の高まりが、TMAの採用を後押ししています。こうしたパートナーシップにより、リソース、専門知識、データの共有が促進され、バイオマーカーの発見と検証の取り組みが世界的に加速されます。

主な課題

  • 複雑さとコスト：組織マイクロアレイ（TMA）技術の複雑さとそれに伴うコストは、小規模の研究所や学術機関にとって大きな参入障壁となります。TMA施設の設置や維持には専門的な機器や専門知識が必要であり、アクセスや導入が制限されます。
  • サンプルの品質と完全性：TMAで使用する組織サンプルの品質と完全性を確保することは、信頼性の高い研究成果を得るために極めて重要です。サンプルの劣化、組織固定方法のばらつき、検体の取り扱いミスなどの課題は、データの正確性と再現性を損なう可能性があります。
  • 限られた標準化：TMAの構築および解析のための標準化されたプロトコールやガイドラインが、異なる研究室や研究環境にわたって欠如しているため、結果にばらつきが生じる可能性があります。このような矛盾は、所見の比較可能性と信頼性を妨げ、TMAの広範な受け入れと採用に影響を与えます。
  • 倫理的および法的考察：患者の同意、プライバシー、規制遵守など、ヒト組織サンプルの使用に関する倫理的懸念は、TMA研究における課題です。厳格な倫理基準を遵守し、複雑な法的枠組みを通過することは、研究スケジュールを遅らせ、運営コストを増加させる可能性があります。
  • データ解釈の課題：分子プロファイリングやバイオマーカーの検証を含め、TMAから生成された大量のデータを分析・解釈するには、高度なバイオインフォマティクスの専門知識が必要です。研究者は、複雑なデータを統合し、臨床的に実用的な知見に変換するという課題に直面しています。
  • 高品質の抗体の入手が限られている：TMA研究における免疫組織化学（IHC）に使用される抗体の入手可能性と質は、アッセイの再現性と信頼性に影響を与える可能性があります。組織タイプや実験条件の違いによる抗体の性能のばらつきは、バイオマーカーの検証作業を複雑にしています。

主要動向

  • デジタルパソロジーの統合：組織マイクロアレイ解析におけるデジタル病理ソリューションの採用が増加しており、高解像度イメージング、データへのリモートアクセス、高度な画像解析機能が容易になり、研究および診断の効率と精度が向上しています。
  • 自動化とハイスループット技術：TMA構築および解析プロセスの自動化とハイスループット技術の進歩により、研究者はより大量のサンプルを扱い、バイオマーカー探索を加速し、実験の再現性を向上させることができます。
  • がん研究以外の拡大：TMAは腫瘍学以外にも、神経学、循環器学、感染症、その他の医療専門分野でのバイオマーカーや疾患メカニズムの研究に応用されることが増えており、その有用性と市場範囲は拡大しています。
  • 個別化医療への取り組み：個別化医療が重視されるようになり、標的治療のための患者特異的バイオマーカーの同定、治療成績の改善、副作用の軽減においてTMAの需要が高まっています。
  • バイオマーカー探索の進歩：次世代シーケンシング（NGS）やマルチオミクス・アプローチなど、分子技術の絶え間ない革新により、TMAにおけるバイオマーカー探索の感度と特異性が向上し、疾患経路や治療標的に関する新たな知見が明らかになりつつあります。

目次

第1章 イントロダクション

  • 市場の定義
  • 市場セグメンテーション
  • 調査手法

第2章 エグゼクティブサマリー

  • 主な調査結果
  • 市場概要
  • 市場ハイライト

第3章 市場概要

  • 市場規模と成長の可能性
  • 市場動向
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • ポーターのファイブフォース分析

第4章 組織マイクロアレイ市場：手技別

  • 免疫組織化学（IHC）
  • 蛍光in situハイブリダイゼーション（FISH）
  • in situハイブリダイゼーション（ISH）
  • その他の手技

第5章 組織マイクロアレイ市場：技術別

  • ポリメラーゼ連鎖反応（PCR）
  • 次世代シーケンサー（NGS）
  • DNAマイクロアレイ
  • その他の技術

第6章 組織マイクロアレイ市場：エンドユーザー別

  • 製薬・バイオテクノロジー企業
  • 調査機関
  • その他のエンドユーザー

第7章 地域別分析

  • 北米
  • 米国
  • カナダ
  • メキシコ
  • 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • ラテンアメリカ
  • ブラジル
  • アルゼンチン
  • チリ
  • 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第8章 市場力学

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • COVID-19の市場への影響

第9章 競合情勢

  • 主要企業
  • 市場シェア分析

第10章 企業プロファイル

  • Novus Biologicals
  • OriGene Technologies, Inc.
  • ProteoGenex
  • PREMIER Biosoft
  • BioIVT
  • Aldila Life Sciences, LLC
  • SunLink Bioscience Inc.
  • HistoGenex
  • US BioSupply
  • CapitalBio Corporation
  • IMPATH, LLC
  • GeneTex, Inc.
  • Rockland Immunochemicals Inc.
  • Abnova Corporation
  • LGC Limited
  • Creative Biolabs
  • Cergentec Corporation
  • BioMax
  • Anatomical Pathology Services, Inc.（APS）
  • Tissue Solutions

第11章 市場の展望と機会

  • 新興技術
  • 今後の市場動向
  • 投資機会

第12章 付録

  • 略語リスト
  • 出典と参考文献
目次
Product Code: 36217

Tissue Microarray Market Size And Forecast

Tissue Microarray Market size was valued at USD 11.17 Billion in 2024 and is projected to reach USD 21.29 Billion by 2032, growing at a CAGR of 10.04% from 2026 to 2032.

  • A tissue microarray (TMA) is a high-throughput technology used in molecular pathology and research to analyze multiple tissue samples simultaneously on a single microscope slide. TMAs enable efficient examination of gene expression, protein localization, and molecular markers across hundreds to thousands of tissue specimens in a single experiment.
  • TMAs are extensively used in oncology research to study tumor heterogeneity, identify biomarkers, and correlate molecular profiles with clinical outcomes. They facilitate large-scale screening of tissue samples for potential therapeutic targets and prognostic indicators.
  • Pharmaceutical companies utilize TMAs to evaluate drug efficacy and toxicity on various tissue types. TMAs enable rapid screening of potential drug candidates against specific biomarkers or cellular pathways implicated in diseases.
  • In clinical settings, TMAs aid in diagnosing diseases by assessing tissue samples for specific molecular markers or genetic abnormalities. They support pathologists in making informed decisions regarding patient prognosis and treatment strategies.
  • Continued advancements in TMA technology, such as improved automation, higher sample throughput, and enhanced imaging and data analysis techniques, will further streamline research workflows and increase efficiency.

Global Tissue Microarray Market Dynamics

The key market dynamics that are shaping the global tissue microarray market include:

Key Market Drivers

  • Advancements in Precision Medicine: The shift towards personalized medicine, driven by the need for targeted therapies based on individual patient profiles, is a significant driver of the tissue microarray market. TMAs enable researchers to identify and validate biomarkers that can predict treatment responses and patient outcomes more accurately.
  • Rising Incidence of Cancer: The increasing prevalence of cancer worldwide fuels demand for innovative tools like TMAs that facilitate comprehensive molecular profiling of tumor tissues. TMAs play a crucial role in oncology research by identifying biomarkers associated with cancer progression, metastasis, and therapeutic resistance.
  • Technological Advancements: Continuous advancements in TMA technologies, such as automation, digital imaging, and high-throughput analysis capabilities, enhance efficiency and accuracy in biomarker discovery and validation studies. These technological innovations attract researchers by offering faster turnaround times and improved data quality.
  • Growing Focus on Biomarker Research: There is a growing emphasis on biomarker discovery across various diseases, not just cancer. TMAs are instrumental in exploring biomarkers associated with neurodegenerative disorders, cardiovascular diseases, and infectious diseases, expanding their application beyond oncology.
  • Drug Development and Clinical Trials: Pharmaceutical companies rely on TMAs to identify biomarkers that can predict drug responses and toxicity profiles during drug development and clinical trials. TMAs streamline the selection of patient cohorts and improve the efficiency of therapeutic development processes.
  • Collaborative Research Initiatives: Increasing collaborations between academic institutions, research organizations, and biotechnology firms drive the adoption of TMAs. These partnerships facilitate shared resources, expertise, and data, accelerating biomarker discovery and validation efforts globally.

Key Challenges:

  • Complexity and Cost: The complexity of Tissue Microarray (TMA) technology and the associated costs pose significant barriers to entry for smaller research laboratories and academic institutions. Setting up and maintaining TMA facilities require specialized equipment and expertise, limiting accessibility and adoption.
  • Sample Quality and Integrity: Ensuring the quality and integrity of tissue samples used in TMAs is crucial for reliable research outcomes. Challenges such as sample degradation, variability in tissue fixation methods, and specimen handling errors can compromise data accuracy and reproducibility.
  • Limited Standardization: Lack of standardized protocols and guidelines for TMA construction and analysis across different laboratories and research settings can lead to variability in results. This inconsistency hinders comparability and reliability of findings, impacting the broader acceptance and adoption of TMAs.
  • Ethical and Legal Considerations: Ethical concerns regarding the use of human tissue samples, including patient consent, privacy, and regulatory compliance, present challenges in TMA research. Adhering to stringent ethical standards and navigating complex legal frameworks can delay research timelines and increase operational costs.
  • Data Interpretation Challenges: Analyzing and interpreting large volumes of data generated from TMAs, including molecular profiling and biomarker validation, requires advanced bioinformatics expertise. Researchers face challenges in integrating and translating complex data into clinically actionable insights.
  • Limited Availability of High-Quality Antibodies: The availability and quality of antibodies used for immunohistochemistry (IHC) in TMA studies can impact assay reproducibility and reliability. The variability in antibody performance across different tissue types and experimental conditions complicates biomarker validation efforts.

Key Trends

  • Integration of Digital Pathology: Increasing adoption of digital pathology solutions in tissue microarray analysis facilitates high-resolution imaging, remote access to data, and advanced image analysis capabilities, enhancing efficiency and accuracy in research and diagnostics.
  • Automation and High-Throughput Technologies: Automation of TMA construction and analysis processes, coupled with advancements in high-throughput technologies, enables researchers to handle larger sample volumes, accelerate biomarker discovery, and improve experimental reproducibility.
  • Expansion beyond Cancer Research: TMAs are increasingly applied beyond oncology to study biomarkers and disease mechanisms in neurology, cardiology, infectious diseases, and other medical specialties, broadening their utility and market scope.
  • Personalized Medicine Initiatives: Growing emphasis on personalized medicine drives the demand for TMAs in identifying patient-specific biomarkers for targeted therapies, improving treatment outcomes, and reducing adverse effects.
  • Advancements in Biomarker Discovery: Continuous innovations in molecular techniques, such as next-generation sequencing (NGS) and multi-omics approaches, are enhancing the sensitivity and specificity of biomarker discovery in TMAs, unlocking new insights into disease pathways and therapeutic targets.

Global Tissue Microarray Market Regional Analysis

Here is a more detailed regional analysis of the global tissue microarray market:

North America

  • North America stands as the dominant region in the tissue microarray sector. The region boasts advanced healthcare infrastructure with state-of-the-art facilities and resources conducive to cutting-edge biomedical research and clinical diagnostics using tissue microarrays. This infrastructure supports efficient sample handling, processing, and analysis, critical for high-quality research outcomes.
  • North America benefits from substantial public and private research funding allocated to biomedical research, including initiatives focused on biomarker discovery and personalized medicine. This funding fuels innovation and drives advancements in tissue microarray technologies and applications.
  • The presence of leading biotechnology and pharmaceutical companies in North America enhances the tissue microarray market. These companies invest heavily in research and development, leveraging tissue microarrays to accelerate drug discovery, biomarker validation, and clinical trials.
  • North America exhibits high adoption rates of advanced technologies such as digital pathology and next-generation sequencing (NGS). These technologies enhance the precision, scalability, and efficiency of tissue microarray studies, enabling researchers to conduct comprehensive molecular profiling and biomarker analysis with greater accuracy.

Asia Pacific

  • Asia-Pacific is experiencing rapid expansion in the tissue microarray market. Increased healthcare spending across the Asia-Pacific region is fueling demand for advanced diagnostic tools and technologies like tissue microarrays. This investment supports enhanced healthcare infrastructure and services, facilitating the adoption of innovative biomedical research techniques.
  • Countries such as China, India, and Japan are expanding their research capabilities in biotechnology and molecular diagnostics. Academic institutions, research centers, and biotechnology firms are increasingly leveraging tissue microarrays to advance biomarker discovery, disease research, and personalized medicine initiatives.
  • There is a growing awareness and adoption of personalized medicine concepts in Asia-Pacific. Tissue microarrays play a crucial role in identifying patient-specific biomarkers and therapeutic targets, aligning with the region's focus on delivering targeted and effective healthcare solutions.
  • Adoption of digital pathology solutions and automation technologies is on the rise across Asia-Pacific. These advancements improve the efficiency and accuracy of tissue microarray studies by enabling rapid sample processing, high-resolution imaging, and automated data analysis. This technological integration supports broader applications of tissue microarrays in clinical diagnostics and biomedical research.

Global Tissue Microarray Market Segmentation Analysis

The Global Tissue Microarray Market is Segmented on the basis of Procedure, Technology, End-User, And Geography.

Tissue Microarray Market, By Procedure

  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)

Based on Procedure, the Global Tissue Microarray Market is bifurcated Immunohistochemistry (IHC) and In Situ Hybridization (ISH). In the tissue microarray market, immunohistochemistry (IHC) currently dominates as the leading procedure. IHC is widely utilized for visualizing protein expression and localization in tissue samples, providing critical insights into disease mechanisms, biomarker expression, and cellular interactions. Its widespread adoption across biomedical research, clinical diagnostics, and drug development sectors underscores its importance in studying tissue microarrays with high specificity and sensitivity. In situ hybridization (ISH) emerges as the second most rapidly growing procedure in the tissue microarray market.

Tissue Microarray Market, By Technology

  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • DNA Microarray

Based on Technology, the Global Tissue Microarray Market is bifurcated into Polymerase chain reaction (PCR), Next-Generation Sequencing (NGS), and DNA Microarray. In the tissue microarray market, polymerase chain reaction (PCR) technology currently dominates as the leading segment. PCR is widely utilized in tissue microarrays for its high sensitivity and specificity in amplifying DNA and RNA sequences, making it indispensable for detecting genetic mutations, gene expression levels, and infectious agents in tissue samples. Its established reliability and versatility in molecular diagnostics and research applications contribute to its widespread adoption across pharmaceutical, biotechnological, and research sectors. Next-generation sequencing (NGS) emerges as the second most rapidly growing technology segment in the tissue microarray market.

Tissue Microarray Market, By End-User

  • Pharmaceutical and Biotechnological Companies
  • Research Organizations

Based on End-User, the Global Tissue Microarray Market is bifurcated Pharmaceutical and Biotechnological Companies and Research Organizations. In the tissue microarray market, pharmaceutical and biotechnological companies dominate as the leading end-user segment. These companies heavily invest in tissue microarrays to accelerate drug discovery, biomarker identification, and clinical trials. Their robust research and development pipelines, coupled with substantial financial resources, drive extensive adoption of tissue microarrays for advancing precision medicine and therapeutic development. Research organizations represent the second most rapidly growing segment in the tissue microarray market.

Tissue Microarray Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on Geography, the Global Tissue Microarray Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the tissue microarray market, North America currently dominates as the leading segment, driven by advanced healthcare infrastructure, substantial research funding, and a strong presence of biotechnology and pharmaceutical industries. The region's early adoption of advanced technologies like digital pathology and next-generation sequencing (NGS) further enhances its market leadership. Meanwhile, Asia Pacific emerges as the second most rapidly growing segment.

Key Players

The "Global Tissue Microarray Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Novus Biologicals, OriGene Technologies, Inc., ProteoGenex, PREMIER Biosoft, BioIVT, SunLink Bioscience, Inc., HistoGenex, US BioSupply.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Tissue Microarray Market Key Developments

  • In September 2023, Thermo Fisher Scientific launched a new range of Tissue Microarray (TMA) products aimed at enhancing efficiency in cancer research. These TMAs feature improved sample density and compatibility with high-throughput analysis techniques, catering to the growing demand for advanced molecular pathology tools.
  • In June 2023, BioGenex introduced the Xmatrx Infinity Tissue Microarrayer, a next-generation platform designed to automate the construction of TMAs with precision and scalability. This system offers enhanced workflow efficiency and accuracy in biomarker discovery and validation studies.
  • In March 2023, Merck KGaA expanded its Tissue Diagnostics portfolio with the acquisition of a leading TMA technology provider. This strategic move aims to strengthen Merck's capabilities in tissue-based research and personalized medicine, positioning the company as a key player in the global TMA market.
  • In December 2022, Sakura Finetek launched the Tissue-Tek TMA System, featuring advanced software for digital pathology integration and analysis. This system enhances the speed and accuracy of TMA construction and analysis, supporting researchers in oncology and other biomedical fields.
  • In October 2022, Agilent Technologies introduced the SurePrint G3 Human Tissue Microarray, offering researchers comprehensive coverage of human tissue samples for biomarker discovery and validation. This TMA platform leverages Agilent's expertise in genomic technologies to accelerate research in personalized medicine and oncology.

TABLE OF CONTENTS

1. Introduction

  • Market Definition
  • Market Segmentation
  • Research Methodology

2. Executive Summary

  • Key Findings
  • Market Overview
  • Market Highlights

3. Market Overview

  • Market Size and Growth Potential
  • Market Trends
  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Porter's Five Forces Analysis

4. Tissue Microarray Market, By Procedure

  • Immunohistochemistry (IHC)
  • Fluorescence in situ hybridization (FISH)
  • In situ hybridization (ISH)
  • Other procedures

5. Tissue Microarray Market, By Technology

  • Polymerase chain reaction (PCR)
  • Next-generation sequencing (NGS)
  • DNA microarray
  • Other technologies

6. Tissue Microarray Market, By End User

  • Pharmaceutical and biotechnological companies
  • Research organizations
  • Other end users

7. Regional Analysis

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Latin America
  • Brazil
  • Argentina
  • Chile
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

8. Market Dynamics

  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Impact of COVID-19 on the Market

9. Competitive Landscape

  • Key Players
  • Market Share Analysis

10. Company Profiles

  • Novus Biologicals
  • OriGene Technologies, Inc.
  • ProteoGenex
  • PREMIER Biosoft
  • BioIVT
  • Aldila Life Sciences, LLC
  • SunLink Bioscience Inc.
  • HistoGenex
  • US BioSupply
  • CapitalBio Corporation
  • IMPATH, LLC
  • GeneTex, Inc.
  • Rockland Immunochemicals Inc.
  • Abnova Corporation
  • LGC Limited
  • Creative Biolabs
  • Cergentec Corporation
  • BioMax
  • Anatomical Pathology Services, Inc. (APS)
  • Tissue Solutions

11. Market Outlook and Opportunities

  • Emerging Technologies
  • Future Market Trends
  • Investment Opportunities

12. Appendix

  • List of Abbreviations
  • Sources and References